Highlights
- Nordicus Partners shares closed at US$2.87 on 16 November 2026, up 14.34%, with Market Capitalisation near US$55.8 million.
- Trading moved from the OTCQB to the Nasdaq Capital Market with the open of Business on 30 October 2026.
- Subsidiary Bio-Convert received a toxicity Waiver from the Danish Medicines Agency, and GMP Manufacturing is on track for December 2026.
- The group's programs include Orocidin for periodontitis and NoviThera for psoriasis, forming a diversified life-sciences holding structure.
A recent uplisting continues to shape the story for a small life-sciences holding company. Nordicus Partners Corporation (NASDAQ:NORD) closed at US$2.87 on 16 November 2026, up 14.34%, on Volume of 27.65 thousand shares. The Beverly Hills-based group moved from the OTCQB to the Nasdaq Capital Market on 30 October 2026.
Trading Overview
Volume was about twice the recent average, and market capitalisation reached around US$55.8 million. The company's latest disclosed developments did not point to a single announcement on the day, so the move is presented as general trading activity following its new listing.
Uplistings from the OTC market to a national exchange often bring wider investor access, though they also bring more demanding reporting and governance requirements.
Relative volume of 2.06 indicates trading about twice the recent average, which is notable for a stock with a Market Value under US$60 million. Thinly traded names can see exaggerated moves when a handful of buyers are active. Prices can therefore reverse as quickly as they rise.
A Life-Sciences Holding Structure
Nordicus Partners operates as a Holding Company with several subsidiaries. Orocidin is developing QR-01 for periodontitis, a gum disease. NoviThera is developing QR-04 for psoriasis, a chronic skin condition. Bio-Convert focuses on manufacturing and conversion technology.
The structure spreads activity across several programs, although each depends on separate development steps and funding.
Periodontitis is a serious gum infection that can damage the tissue supporting teeth, while psoriasis is an immune-mediated skin disease affecting millions worldwide. Both have existing treatments, so new candidates must show benefits in safety, effectiveness or convenience.
Regulatory and Manufacturing Progress
Bio-Convert received a toxicity waiver from the Danish Medicines Agency, a regulatory step that can reduce the testing required ahead of clinical work. Good manufacturing practice, or GMP, production is on track for December 2026.
The company provided a corporate update on 6 February 2026, outlining its structure and priorities ahead of its Nasdaq application.
In general, a toxicity waiver can shorten the path to first studies in humans by reducing the need for certain nonclinical work. The final scope of studies still depends on regulators in each market.
Risks and What to Watch
Early-stage life-sciences companies face development, regulatory and funding risks, and a holding structure adds the complexity of managing several programs. Nasdaq listing also requires continuing compliance with minimum standards.
Investors may follow the December manufacturing milestone, clinical planning for QR-01 and QR-04, and any financing that follows the uplisting.
Companies that move to Nasdaq must maintain minimum bid price, Equity and governance standards, and compliance is reviewed over time.
_11_17_2026_06_50_14_402066.jpg)





Please wait processing your request...